Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCL (Fludarabine, Cyclophosphamide, Lenalidomide) in Relapsed/Refractory CLL
NCT00727415Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Feb 2008
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in chronic lymphocytic leukemia (CLL), sponsored by GIMEMA. Primary endpoints: Maximum Tolerated Dose of Lenalidomide and Overall Complete Response Rate at 6 months. Started Feb 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00727415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00727415.